Clinical trials: Tacrolimus
Carcinoma, Non-Small-Cell Lung
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care…
- Trial name
- COCOON (NCT06120140)
- Testing
- Amivantamab IV, Amivantamab SC, Lazertinib
- Where
- 93 sites in United States, Argentina and 9 more
- Volunteers
- 305 people
- Sponsor
- Janssen Research & Development, LLC
Cardiac Allograft Vasculopathy, Heart Transplant Recipients
Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation
All people who have a heart transplant are at risk for developing cardiac allograft vasculopathy (CAV). CAV means narrowing of the heart transplant vessels, which is associated with poor heart transplant function.
- Trial name
- NCT01278745
- Testing
- Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
- Where
- 24 sites in United States
- Volunteers
- 362 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplantation, Renal Transplantation
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
The purpose of this study was to assess whether a new drug, Nulojix® (belatacept), would minimize serious long term side effects associated with anti-rejection medications while still protecting the new kidney from damage.
- Trial name
- NCT01436305
- Testing
- Alemtuzumab, MMF, Basiliximab
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant Recipients
Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation
The study will compare how well transplanted kidneys work and the response of people's immune systems as tacrolimus, a calcineurin inhibitor (CNI), is withdrawn.
- Trial name
- NCT01517984
- Testing
- Tacrolimus (CNI) Withdrawal, Standard Immunosuppressive Therapy
- Where
- 11 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Simultaneous Kidney and Pancreas Transplantation
Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation
The purpose of this study is to find out if the drug NULOJIX® (belatacept) will minimize the amount of other anti-rejection medications necessary and thereby reduce the long-term side effects caused by the other medications.
- Trial name
- NCT01790594
- Testing
- Belatacept, methylprednisolone, Anti-thymocyte Globulin (Rabbit)
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Primary Renal Allograft Candidate, Kidney Transplantation
Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen
The primary objective is to evaluate a NULOJIX® (belatacept) based regimens as a means of improving long-term graft function without increasing the risks of immunologic graft injury by avoiding both calcineurin inhibitors (CNIs)…
- Trial name
- NCT01856257
- Testing
- Anti-thymocyte Globulin (Rabbit), belatacept, methylprednisolone
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant
Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
During transplant surgery, there is a period of time when a donated kidney is removed from a donor's body and stored until the time of the transplant surgery.
- Trial name
- NCT02495077
- Testing
- Infliximab, Methylprednisolone, Mycophenolate Mofetil
- Where
- 15 sites in United States, Canada
- Volunteers
- 290 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant, Adult Living Donor Kidney Transplant Recipients
Treg Therapy in Subclinical Inflammation in Kidney Transplantation
The purpose of this study is: To see if polyTregs can reduce inflammation in a transplanted kidney. To find out what effects, good or bad, polyTregs will have in the kidney recipient.
- Conditions
- Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant, Living Kidney Donor
- Trial name
- TASK (NCT02711826)
- Testing
- Polyclonal Regulatory T Cells, Everolimus, Tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sickle Cell Disease
Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation
This study aims to enroll 58 pre-adolescent (<13 years) pediatric participants with sickle cell disease (SCD) who have a pre-adolescent sibling bone marrow donor.
- Trial name
- NCT04018937
- Testing
- Alemtuzumab, Fludarabine, Melphalan
- Where
- 15 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- Emory University
Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum
Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
The goal of this prospective phase 2 study is to assess the efficacy and safety of intestinal or multivisceral transplantation for participants with PMP not amenable to other curative-intent treatments.
- Conditions
- Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum, Pseudomyxoma Peritonei
- Trial name
- TRANSCAPE (NCT06084780)
- Testing
- Intestinal, Multivisceral or Modified Multivisceral Transplantation, Alemtuzumab, Tacrolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Myeloid Leukemia
Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
This is a standard phase 2 study powered to demonstrate improvement in the 100 day leukemia free survival to 30% from <10% expected with the use of reduced intensity haplo-HCT in this extremely high-risk patient cohort (based on…
- Trial name
- NCT02782546
- Testing
- Graft cell infusion, Tacrolimus, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Washington University School of Medicine
Primary Membranous Nephropathy
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
- Trial name
- OLYMPUS (NCT07204275)
- Testing
- Povetacicept, Tacrolimus
- Where
- 115 sites in United States, Australia and 12 more
- Volunteers
- 176 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Liver Transplant
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function.
- Trial name
- ELIMINATE (NCT06280950)
- Testing
- Everolimus, Tacrolimus (continued reduction), Tacrolimus (maintain 50% reduction)
- Where
- 12 sites in United States
- Volunteers
- 340 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
This trial aims to find the MTD of Venetoclax when added to Fludarabin, Amsacrine and Ara-C + Treosulfan and to evaluate whether the addition of Venetoclax to sequential conditioning with FLAMSA + Treosulfan is safe for…
- Conditions
- Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT05807932
- Testing
- Venetoclax, Amsacrine, Ara-C
- Where
- 6 sites in Germany
- Volunteers
- 38 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Splenomegaly, Myelofibrosis
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
To learn if giving ruxolitinib and busulfan before a stem cell transplant can help to reduce spleen size and help the transplant to succeed.
- Trial name
- NCT06345495
- Testing
- Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Transplant; Complications, Renal Insufficiency
Extended-Release Tacrolimus Following Liver Transplantation
Medications used after transplant to prevent rejection are associated with many side effects. Tacrolimus side effects include kidney dysfunction; tremor, headaches, difficulty sleeping, change in sensation (legs), seizure, or…
- Conditions
- Liver Transplant; Complications, Renal Insufficiency, Immunosuppressant Adverse Reaction, Metabolic Syndrome
- Trial name
- NCT05242315
- Testing
- Envarsus Oral Product, Prograf (SOC)
- Where
- Canada
- Volunteers
- 94 people
- Sponsor
- University of Alberta
Atopic Dermatitis (AD)
EFFICACY AND TOLERANCE OF AN EYELID BALM IN COMBINATION WITH TACROLIMUS 0.1% IN PATIENTS WITH EYELID ATOPIC DERMATITIS
The aim of this study is to evaluate the tolerance and efficacy of a new emollient cream specifically dedicated to the eyelid area when applied in association with tacrolimus 0.1% in subjects suffering from eyelid Atopic…
- Trial name
- NCT07819071
- Testing
- Tested Emollient RV5258A, tacrolimus 0.1%
- Where
- Poland
- Volunteers
- 33 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Primary Membranous Nephropathy
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by…
- Trial name
- ALMOND (NCT05707377)
- Testing
- Zanubrutinib, Tacrolimus
- Where
- 45 sites in United States, Brazil and 7 more
- Volunteers
- 178 people
- Sponsor
- BeOne Medicines
Acute Myelogenous Leukemia, Acute Lymphatic Leukemia
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is a complication that can occur after transplant in participants with…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT06680661
- Testing
- Cyclophosphamide, Fludarabine, Thiotepa
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Leland Metheny
Kidney Transplant Recipient
Biomarker-Guided Mycophenolate Mofetil Elimination in Low-Risk Older Adult Kidney Transplant Recipients
Most kidney transplant recipients take a combination of anti-rejection medicines for the rest of their life. One of these is called mycophenolate mofetil (MMF), also known by the brand name CellCept.
- Trial name
- OPTIMA-KT (NCT07806136)
- Testing
- Tacrolimus (Kidney transplant maintenance immunosuppression), Mycophenoate Mofetil, Prednisone (SOC arm)
- Volunteers
- 20 people
- Sponsor
- Virginia Commonwealth University